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a  b  s  t  r  a  c  t
Elevated  levels  of  low-density  lipoprotein  cholesterol  (LDL-C)  increase  the  risk  of coronary  heart  disease
(CHD), but  pharmacologic  therapy  to decrease  LDL-C  signiﬁcantly  reduces  the  risk  of  cardiovascular
events.  Despite  the  effectiveness  of  statin  therapy,  there  remains  signiﬁcant  residual  cardiovascular  risk.
A  low  plasma  concentration  of  high-density  lipoprotein  cholesterol  (HDL-C)  is  associated  with  increased
risk  of  CHD.  Moreover,  recent  studies  have  shown  that HDL-C  levels  during  statin  treatment  remaineywords:
igh-density lipoprotein cholesterol
ow-density lipoprotein cholesterol
tatin
oronary heart disease
therosclerosis
an independent  predictor  of  the risk  of cardiovascular  events.  However,  recent  clinical  trials  aimed  at
reducing  CHD  risk  by  raising  HDL-C  levels  have  not  shown  satisfactory  results  and it is  becoming  evident
that  a functional  HDL-C  is  a  more  desirable  target  than  simply  elevating  its level.  This  review  summarizes
the  function  of HDL-C  in reverse  cholesterol  transfer  from  peripheral  tissue  and  discusses  the  latest
HDL-targeting  therapeutic  strategies  including  the  manipulation  of microRNAs.icroRNA ©  2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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ntroduction
Although the lowering of low-density lipoprotein cholesterol
LDL-C) with the use of statins has revolutionized the treatment
f atherosclerotic cardiovascular disease, statins can only reduce
he risk of cardiovascular events by up to 30–40% depending
n the disease status and the amount of statin used, which still
eaves a large burden of residual disease risk [1–3]. Recent stud-
es have shown that high-density lipoprotein cholesterol (HDL-C)
evels during statin treatment remain an independent predictor
relationship between the HDL-C concentration and cardiovascular
risk. In fact, a 1 mg/dl (0.026 mM)  increment in HDL-C levels was
associated with a signiﬁcant decrease in the risk of coronary heart
disease (CHD) of 2% in men  and 3% in women  [5].
These data led to the conclusion that current treatment strate-
gies for reducing CHD risk are insufﬁcient to prevent most CHD
events, and the development of therapies that raise HDL-C is nec-
essary to reduce cardiovascular diseases in the midst of the “statin
era” in the management of atherosclerosis. However, convinc-f the risk for cardiovascular events in patients who have been
reated with statins to lower LDL-C levels [4].  Clinical and epi-
emiologic studies have consistently shown that there is an inverse
∗ Correspondence address: Department of Cardiovascular Medicine, Graduate
chool of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto
06-8507, Japan. Tel.: +81 75 751 3190; fax: +81 75 751 3203.
E-mail address: kohono@kuhp.kyoto-u.ac.jp
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.07.014ing epidemiologic data linking HDL-C and CHD risk have not yet
translated into solid evidence. There are no clinical trials that sup-
port linearity between HDL-C increases and CHD risk reduction.
The recent negative results obtained by the ILLUMINATE [6] and
AIM-HIGH trials [7] suggest that HDL-C increases by the strate-
gies tested may  not always be beneﬁcial for the reduction of CHD
risk. The metabolic heterogeneity of HDL particles may  underlie
the inconsistency between epidemiologic studies and experimen-
tal approaches in clinical trials of lipid treatments. HDL  comprises
vier Ltd. All rights reserved.
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Nig. 1. Schematic diagram of RCT. ABCA1, ATP-binding cassette transporter A1; ap
hol,  cholesterol; HDL, high-density lipoprotein cholesterol; LCAT, lecitin-choleste
everse cholesterol transfer; SR-BI, scavenger receptor class B type I; TG, triglycerid
any types of lipoproteins, lipids, proteins, and nucleotides that
nﬂuence the functions and metabolism of the particles, and there
re substantial differences in their size and density [8].  Thus, several
eports already suggested that subpopulations of HDL have more or
ess anti-atherogenic potential [9].  All of these results have led to a
uest to ﬁnd new strategies to reduce CHD events by improving the
uality and quantity of HDL-C. This review summarizes the func-
ion of HDL-C in reverse cholesterol transfer (RCT) from peripheral
issue (Fig. 1) and discusses the recent discovery of the function of
icroRNAs (miRs) in HDL metabolism.
urrent lipid management therapy and HDL-C
Management of dyslipidemia in patients with cardiovascular
isease should be started with statin therapy. In patients with low
DL-C, statins are effective in reducing the absolute cardiovascu-
ar event rate. However, it has been noted that the residual risk of
HD events is still high. It is known that statins can increase HDL-C
evels by 5–10%. Although the mechanisms of increasing HDL-C are
till unclear, it is suggested that statins can stimulate ATP-binding
assette transporter (ABC) A1 expression in the liver through a
iver-speciﬁc promoter element [10]. Statins also appear to reduce
he rates of endogenous cholesteryl ester transfer protein (CETP)-
ediated cholesteryl ester (CE) transfer from HDL by decreasing the
uantity of apolipoprotein (apo) B lipoproteins available to accept
E from HDL. Moreover, some statins are known to enhance hepatic
poA-I production, which increases the production of nascent HDL-
 [11].
Other pharmacologic reagents for the treatment of dyslipidemia
ncluding niacin, ﬁbrates, and peroxisome proliferator-activated
eceptor (PPAR) agonists have the potential to raise HDL-C lev-
ls. Among them, niacin, or nicotinic acid, which is a soluble B
itamin, is known as the most effective drug approved for rais-
ng HDL-C levels. In clinical trials, it has been shown to lower
DL-C levels by 10–20%, triglyceride by 20–40%, and lipoprotein
Lp) (a) by 10–30%, as well as raise HDL-C levels by 15–30% [12].
iacin appears to increase HDL-C levels by decreasing the hepaticapolipoprotein A-I; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein;
yltransferase; LDL, low-density lipoprotein cholesterol; LDLR, LDL-receptor; RCT,
L, very low-density lipoprotein cholesterol.
uptake of apoAI, thereby delaying catabolism [13]. Although niacin
is widely used in the management of dyslipidemia, side effects can
affect compliance with therapy. Its potential side effects are ﬂush-
ing, hepatotoxicity, hyperuricemia, upper gastrointestinal distress,
and hyperglycemia [14]. In comparison with immediate-release
niacin, extended-release formulations result in reduced ﬂushing
symptoms. Thus, extended-release niacin has been used in recent
clinical trials. The AIM-HIGH trial was  designed to examine whether
extended-release niacin added to simvastatin to raise low levels of
HDL-C is superior to simvastatin alone in reducing residual CHD
risk. However, among patients with atherosclerotic cardiovascular
disease and LDL-C levels of less than 70 mg/dl (1.81 mmol/l), there
was no incremental clinical beneﬁt from the addition of niacin to
statin therapy during a 36-month follow-up period, despite sig-
niﬁcant improvements in HDL-C and triglyceride levels [7].  These
results suggest that with the well-controlled statin therapy, there
seem to be no beneﬁcial effects of additional treatment with niacin.
However, beneﬁts of niacin might be observed in higher-risk car-
diac patients or in those whose LDL-C levels are not intensively
controlled by statins, and a further prospective study will be
required.
Evolution of the RCT concept
HDL-C has been proposed to have several anti-atherosclerotic
properties, including the ability to mediate macrophage cholesterol
efﬂux, antioxidant capacity, anti-inﬂammatory properties, nitric
oxide-promoting activity, and an ability to transport proteins with
their own  intrinsic biological activities. HDL particles are critical
acceptors of cholesterol from lipid-laden macrophages and thereby
play an important role in the maintenance of net cholesterol bal-
ance in the arterial wall and in the reduction of proinﬂammatory
responses by lipid-rich macrophages. The idea of RCT, which refers
to the overall ﬂux of cholesterol from the periphery to the liver and
its fecal excretion, was ﬁrst proposed nearly 50 years ago [15,16].
From the earliest proposed concept for HDL-mediated choles-
terol efﬂux, the concentration of the cholesterol content in HDL
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articles has been considered as key to the efﬁciency of the ‘RCT’
rocess. However, the use of static measurements of HDL-C is
n inadequate approach for the characterization of RCT, because
CT involves active ﬂux and passive transport mechanisms from
acrophage foam cells, HDL-modifying enzymes and transporters,
nd hepatic cholesterol receptors.
The RCT concept is also used to refer to speciﬁc steps or spe-
iﬁc cell types in this process, thus it causes confusion sometimes.
acrophage-derived cholesterol represents one of the components
f cholesterol transport by HDL particles. Therefore, cholesterol
fﬂux from macrophage foam cells is referred to as macrophage-
peciﬁc RCT. Even though cholesterol efﬂux from lipid-laden
acrophages contributes a relatively minor amount to the choles-
erol content of HDL particles, macrophage-speciﬁc RCT is thought
o be the major function of lipid-modifying therapies.
echanism and regulation of RCT
The ﬁrst important step in the RCT pathway is the removal of
xcess cholesterol from macrophage-derived foam cells present in
he atherosclerotic plaque. Cholesterol can be efﬂuxed from the
acrophage only in the unesteriﬁed or free form, but not as CE.
ree cholesterol can leave the macrophage by different pathways,
hich either might be transporter-independent or dependent on
holesterol transporters such as scavenger receptor class B type
 (SR-BI), ABCA1, and ABCG1. Ablation of ABCA1 in macrophages
ecreased the ﬂux of cholesterol from foam cells into the serum as
ell as feces [17,18]. The critical role that ABCA1 plays in deter-
ining plasma HDL-C levels is well established. Patients with
angier disease, who are homozygous for mutations of ABCA1,
ave undetectable levels of HDL-C and apoA-I, because of impaired
ipidation and subsequent catabolism of lipid-poor apoA-I. In addi-
ion to ABCA1- and ABCG1-mediated efﬂux, cholesterol can be
fﬂuxed from macrophages to HDL in an SR-BI-dependent pathway.
nother important player in cholesterol efﬂux and machophage-
peciﬁc RCT is lipid-poor apoE produced by macrophages. A
ecent study revealed that in vivo macrophages-to-feces RCT is
iminished in wild-type mice receiving macrophages that are
eﬁcient in apoE [19]. At normal cholesterol levels, aqueous diffu-
ion is predominant, whereas in cholesterol-loaded macrophages,
BC transporters predominate for cholesterol removal. In human
holesterol-loaded THP-1 macrophages, the ABCA1 and SR-BI path-
ays are predominant, whereas ABCG1 does not contribute to
fﬂux [20].
A second essential determinant of efﬁcient cholesterol removal
rom macrophage foam cells is the amount of acceptors such as
poA-I and HDL. ApoA-I constitutes about 70% of the apolipoprotein
ontent of HDL particles; as a result, plasma apoA-I concentra-
ions correlate closely with plasma HDL-C. ApoA-I is secreted
redominantly by the liver and intestine as lipid-poor apoA-I and
ascent cholesterol-poor HDL particles. Nascent apoA-I acquires
hospholipids and cholesterol via cellular efﬂux as well as by trans-
er of surface components of triglyceride (TG)-rich lipoproteins
TRL; chylomicrons and very low-density lipoprotein (VLDL) during
ipoprotein lipase-mediated intravascular lipolysis of TRL. Overex-
ression of human apoA-I in mice resulted in more cholesterol
eing removed from macrophages and deposited in the feces via
he RCT pathway leading strong support to the concept that raising
DL levels protects against atherosclerosis through increasing RCT
21]. Dietary fat, alcohol, estrogen, androgens, thyroid hormone,
etinoids, glucocorticoids, ﬁbrates, niacin, and statins are known to
nﬂuence transcriptional induction of the apoA-I gene. Promotion
f apoA-I induction has been an attractive therapeutic target for
rug development and some of such reagents are undergoing clin-
cal trials. It is known that the naturally occurring apoA-I mutanty 60 (2012) 339–343 341
apoA-I Milano was more effective in stimulating macrophage RCT
than wild-type apoA-I [22]. Administration of the apoA-I mimetic
peptides D-4F, 5A, or ATI-5261 to mice all increased the transfer of
macrophage-derived cholesterol to plasma and feces [23–25].
The association between HDL cholesterol levels and
macrophage-speciﬁc RCT is less straightforward. There are still a
substantial number of patients that experience complications of
CHD despite exhibiting high HDL-C levels and there are individuals
with low plasma HDL-C levels that do not develop clinically
signiﬁcant atherosclerosis. Because regulation and metabolism of
HDL-C is complex and there are several subclasses with different
functions in HDL-C, plasma HDL levels do not necessarily represent
a reliable reﬂection of macrophage RCT rates. Therefore, HDL-C
levels should be used with caution as a surrogate for predicting
ﬂuxes through the RCT pathway.
Lecitin-cholesterol acyltransferase (LCAT) plays an important
role in the maturation of HDL-C. The activity of LCAT is critical to
normal HDL metabolism. In humans, genetic LCAT deﬁciency syn-
dromes are associated with markedly reduced HDL-C and apoA-I
levels and rapid catabolism of apoA-I [26]. However, the impor-
tance of LCAT to the process of RCT has not been ﬁrmly established.
In a recent report, there was no correlation between LCAT choles-
terol esteriﬁcation rates and the amount of macrophage-derived
cholesterol in feces [27].
Hepatic lipase (HL) and endothelial lipase (EL) are both negative
regulators of HDL metabolism. HL- and EL-deﬁcient mice as well as
HL/EL double knockout mice have higher HDL-C than controls but
also decreased uptake of HDL-derived cholesterol into the liver [28].
In these cases, not plasma HDL-C levels but the uptake of cholesterol
into the liver appears to the rate limiting step for the macrophage
RCT pathway.
CETP is a hydrophobic glycoprotein made by liver and adipose
tissue and is important for human lipoprotein metabolism. It pro-
motes the redistribution and equilibration of hydrophobic lipids
packaged within the lipoprotein core between HDL and apo-B-
containing lipoproteins. By facilitating the transfer of CEs from HDL
to apoB-containing lipoproteins, CETP directs hepatic uptake of
cholesterol to the LDL receptor, which is also an important route in
the RCT pathway. In humans, radiolabeled HDL CE excreted into bile
was transported to the liver almost entirely after transfer to apoB-
containing lipoproteins. Moreover, there is increasing data that the
functionality of HDL-Cs may  be an important determinant of their
anti-atherogenic effects. It is not yet clariﬁed whether the large CE-
rich HDL particles that accumulate as a result of CETP inhibition
may  serve as inhibitors for atherogenesis.
Macrophage RCT may  also be inﬂuenced by speciﬁc apolipopro-
teins carried in the HDL particle. HDL-C of coronary artery disease
patients carries distinct apolipoproteins and protein oxidation is
thought to generate dysfunctional HDL-C. Increases in the levels of
HDL-C that contain apoC-III is reported to predict an increase in
coronary artery disease risk.
After transport to the plasma compartment, the next step of RCT
is the delivery of cholesterol from macrophages to the liver. SR-BI,
a member of the scavenger receptor superfamily of proteins, is the
key receptor responsible for the selective uptake of CEs from HDL
into the liver. Catabolism of all major HDL-C can occur by way  of SR-
BI, with the highest uptake constants for CE and free cholesterol.
The importance of SR-BI, which is highly expressed in the liver,
adrenal glands, and ovaries, for HDL metabolism has been readily
demonstrated in genetically altered animals. Mice deﬁcient in SR-BI
have elevated levels of HDL-C but not of plasma apoA-I, consistent
with a defect in selective uptake of HDL-C. Overexpression of SR-BI,
on the other hand, results in reduced plasma concentrations of HDL-
C and apoA-I, because of accelerated renal and hepatic clearance
of cholesterol-depleted HDL-particles after interaction with SR-BI
[29–31]. Thus, SR-BI has been recognized as a positive regulator of
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CT [32]. The LDL receptor is also important in this step because
t takes up CETP-mediated CEs from HDL in apoB-containing
ipoproteins. An alternative mechanism by which HDL-C can be
aken up into the liver is by holoparticle endocytosis [33].
Biliary secretion is the last step of the major route for RCT to
liminate cholesterol from the body. CEs are hydrolyzed by neutral
E hydrolase to generate free cholesterol and excreted into the bile.
ile acids are secreted by the bile salt export pump (or ABCB11).
BCG5 and ABCG8 are obligate heterodimers that mediate secre-
ion of cholesterol and plant sterols into bile together with the
holesterol-binding protein Niemann-Pick C2 [34]. Of note, choles-
erol is reabsorbed by the transport protein Niemann-Pick C1-like
 in the intestine. It has been identiﬁed as the molecular target of
he cholesterol absorption inhibitor ezetimibe [35].
hat are the factors inﬂuencing steps in the RCT pathway?
A major recognized functional property of HDL-C is to elicit
holesterol efﬂux and mediate RCT. Therefore, therapeutic strate-
ies to speciﬁcally enhance RCT would be more beneﬁcial than
hose that simply increase HDL-C levels. There are several factors
nd compounds that inﬂuence steps in the macrophage-speciﬁc
CT pathway.
Because synthetic liver X-receptor (LXR) agonists are known
o induce the transcription of ABCA1 as well as other molecules
nvolved in the RCT pathway, including apoE [36], these compounds
ave been thought to raise HDL-C levels and reduce atherosclerosis.
owever, because of the fact that they induce fatty acid synthesis,
hese compounds have also been shown to cause liver steato-
is, particularly in a mouse model of obesity [37–39].  Recently,
artial LXR agonists that induce ABCA1 and ABCG1 but not fatty
cid synthesis have been reported [40–42].  However, one of these
ompounds caused an increase in adverse neurologic events in indi-
iduals who received higher doses [40].
PPARs are transcription factors that, like LXRs, belong to the
uclear receptor family. Recent studies revealed that the potent
PAR agonist GW7647 increased macrophage RCT [43]. PPAR lig-
nds have attracted interests in view of their potential use for the
reatment of cardiovascular diseases.
Farnesoid X receptor (FXR) has been also implicated in the con-
rol of cholesterol metabolism. Activation of FXR, by treatment with
he speciﬁc agonist GW4064 enhanced the transport of cholesterol
rom macrophages to feces [44]. However, additional experiments
o prove their efﬁcacy and safety are required for therapeutic use.
miRs are small, non-protein-coding RNAs that bind to speciﬁc
RNAs and inhibit translation or promote mRNA degradation.
ecent reports, including ours, have indicated that miR-33 controls
holesterol homeostasis [45–48].  miR-33 deﬁcient mice were gen-
rated and the critical role for miR-33 in the regulation of ABCA1
xpression and HDL biosynthesis was conﬁrmed in vivo [48]. It
as already been reported that silencing miR-33a resulted in a
eduction of atherosclerosis in mice [49]. We  also have conﬁrmed
hat HDL in miR-33 deﬁcient mice has enhanced cholesterol efﬂux
apacity.
In humans, not in rodents, sterol regulatory element binding
rotein 1 (SREBP1) and SREBP2 encode miR-33b and miR-33a,
espectively [46]. It is well known that hypertriglycemia in
etabolic syndrome is caused by the insulin-induced increase in
REBP1c mRNA and protein levels [50,51]. Low HDL often accom-
anies metabolic syndrome and it is possible that the reduction in
DL is caused by a decrease in ABCA1 through the increased pro-
uction of miR-33b from the insulin-induced induction of SREBP1c.
lthough it is impossible to prove this hypothesis in mice mod-
ls that lack miR-33b, antagonizing miR-33 could be a promising
ay to raise HDL levels when the transcription of both SREBPs is
[
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upregulated. Recently, it was  shown that inhibition of miR-33a and
-33b resulted in an increase in plasma HDL and reduction of VLDL
triglycerides in non-human primates [52]. Thus, a combination of
silencing of endogenous miR-33 and statins may  be a useful ther-
apeutic strategy for raising HDL and lowering LDL levels especially
for metabolic syndrome patients.
Conclusion and future directions
In summary, the metabolism of HDL-C involves a complex rela-
tion of factors regulating the synthesis, intravascular remodeling,
and catabolism of HDL-C. Recent investigations indicate that it
is not enough to simply increase HDL-C level but to increase its
function and enhance RCT for the prevention of atherosclerosis
and subsequent CHD. Recent ﬁndings including the function of
miRNAs would clarify yet unknown physiological mechanisms in
macrophage-speciﬁc RCT and provide new strategies to prevent
atherosclerosis and CHD.
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